HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Harnessing the gut to improve cancer outcomes
-
- Should screening of the gut microbiome be standard practice for patients with melanoma?
- Take a look back at the top ovarian cancer news from 2019
- Engaging in conversations about fertility John Sweetenham, MD, FRCP, FACP
- ‘Reproducibility crisis’ in radiation biology research could negatively impact clinical care advances
- Single-port robotic surgery shows promise for urologic cancers and beyond
- Common cold virus could transform bladder cancer treatment
- Studies show oncologists can adapt quickly to new evidence
- Health equity initiatives address cancer ‘within the context of human circumstances’
-
- Participation in molecular tumor board may help patients feel better informed, engaged
- Molecular test shows potential for faster breast cancer diagnosis
- Intervention helps parents cope, find ‘the good in the bad’ after child’s cancer diagnosis
- Biocompatible ‘lab on a chip’ shows potential in development of antiplatelet therapies
- Front-line atezolizumab improves overall survival in advanced NSCLC
- Anti-CD73 antibody agent appears safe, shows promise in advanced cancers
- Sitravatinib plus nivolumab safe, active in advanced urothelial carcinoma
- Novel bispecific immune cell engager safe, clinically beneficial in HER2-positive tumors
-
- Redifferentiation therapy resensitizes some radioactive iodine-refractory thyroid cancer
- Radiofrequency ablation viable option for some with thyroid cancer
- ATA: Ethical, surgical, medical guidelines coming for anaplastic thyroid cancer
- Personalized therapy improves anaplastic thyroid cancer outcomes
- Research underway on essential genes in medullary thyroid cancer
- Pathway key to BRAF V600E-mediated papillary thyroid cancer progression
- Apatinib shows activity in radioactive iodine-refractory differentiated thyroid cancer
- Novel blood tests could improve cancer detection
-
- ASTRO confers honorary member status to Penn oncologist
- FDA announces international collaboration, approves pembrolizumab plus lenvatinib for endometrial cancer
- With equal access to care, prostate cancer outcomes similar among black, white men
- Women underrepresented in leadership of oncologic randomized clinical trials
- Despite evolution of treatment for male breast cancer, gaps in care remain
- BRAF/MEK inhibitor therapy induces response in metastatic melanoma with rare BRAF mutations
- Colorectal cancer incidence among younger US adults continues to rise
- Palliative care linked to survival benefit in advanced lung cancer
-
- Default order in EMR reduces unnecessary imaging for patients with advanced cancer
- Physical fitness linked to neurocognitive outcomes of leukemia survivors
- Antibiotics thwart disease activity in advanced cutaneous T-cell lymphoma
- Racial disparities observed in treatment of multiple myeloma
- Anti-EGFR therapy effective for certain patients with BRAF-mutant colorectal cancer
- Power morcellation technique increases mortality risk for women with occult uterine sarcoma
- Plasma cell-free DNA may predict glioblastoma progression
- Antidepressant use linked to slightly increased risk for subdural hematoma
-
- FDA expands Erleada approval for prostate cancer
- FDA approves Darzalex-based combination for first-line multiple myeloma treatment
- FDA grants breakthrough therapy designation to tepotinib for lung cancer subset
- FDA grants orphan drug designation to Nerlynx for breast cancer brain metastases
- The University of Alabama at Birmingham names cancer center director
- ASH presents bridge grants to 19 investigators
- University of Chicago professor receives ESMO Award for Immuno-Oncology